BR112022013991A2 - Formulação para tratar uma doença ou distúrbio tratável por um agonista do receptor de adenosina a3 (a3ar), canabinoide, método de tratamento de uma doença ou distúrbio tratável por um agonista do receptor de adenosina a3 (a3ar) e método de tratamento de uma doença ou distúrbio em um sujeito - Google Patents

Formulação para tratar uma doença ou distúrbio tratável por um agonista do receptor de adenosina a3 (a3ar), canabinoide, método de tratamento de uma doença ou distúrbio tratável por um agonista do receptor de adenosina a3 (a3ar) e método de tratamento de uma doença ou distúrbio em um sujeito

Info

Publication number
BR112022013991A2
BR112022013991A2 BR112022013991A BR112022013991A BR112022013991A2 BR 112022013991 A2 BR112022013991 A2 BR 112022013991A2 BR 112022013991 A BR112022013991 A BR 112022013991A BR 112022013991 A BR112022013991 A BR 112022013991A BR 112022013991 A2 BR112022013991 A2 BR 112022013991A2
Authority
BR
Brazil
Prior art keywords
disease
treatment
a3ar
adenosine
disorder
Prior art date
Application number
BR112022013991A
Other languages
English (en)
Inventor
Fishman Pnina
Itzhak Inbal
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of BR112022013991A2 publication Critical patent/BR112022013991A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULAÇÃO PARA TRATAR UMA DOENÇA OU DISTÚRBIO TRATÁVEL POR UM AGONISTA DO RECEPTOR DE ADENOSINA A3 (A3AR), CANABINOIDE, MÉTODO DE TRATAMENTO DE UMA DOENÇA OU DISTÚRBIO TRATÁVEL POR UM AGONISTA DO RECEPTOR DE ADENOSINA A3 (A3AR) E MÉTODO DE TRATAMENTO DE UMA DOENÇA OU DISTÚRBIO EM UM SUJEITO. Trata-se de canabinoides usados para tratar doenças ou distúrbios tratáveis por um ativador do receptor de adenosina A3 (A3AR). O efeito do canabinoide é exercido através do A3AR. Os canabinoides podem ser selecionados a partir de fitocanabinoides naturais, derivados sintéticos de fitocanabinoides, extratos da planta cannabis e outros.
BR112022013991A 2020-01-16 2021-01-14 Formulação para tratar uma doença ou distúrbio tratável por um agonista do receptor de adenosina a3 (a3ar), canabinoide, método de tratamento de uma doença ou distúrbio tratável por um agonista do receptor de adenosina a3 (a3ar) e método de tratamento de uma doença ou distúrbio em um sujeito BR112022013991A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL272078A IL272078A (en) 2020-01-16 2020-01-16 Cannabinoids for use in therapy
PCT/IL2021/050046 WO2021144799A1 (en) 2020-01-16 2021-01-14 Cannabinoids for use in treatment

Publications (1)

Publication Number Publication Date
BR112022013991A2 true BR112022013991A2 (pt) 2022-10-11

Family

ID=76863896

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013991A BR112022013991A2 (pt) 2020-01-16 2021-01-14 Formulação para tratar uma doença ou distúrbio tratável por um agonista do receptor de adenosina a3 (a3ar), canabinoide, método de tratamento de uma doença ou distúrbio tratável por um agonista do receptor de adenosina a3 (a3ar) e método de tratamento de uma doença ou distúrbio em um sujeito

Country Status (11)

Country Link
US (1) US20230049415A1 (pt)
EP (1) EP4090324A1 (pt)
JP (1) JP2023510003A (pt)
KR (1) KR20220137661A (pt)
CN (1) CN114980873A (pt)
AU (1) AU2021207766A1 (pt)
BR (1) BR112022013991A2 (pt)
CA (1) CA3164880A1 (pt)
IL (1) IL272078A (pt)
MX (1) MX2022008850A (pt)
WO (1) WO2021144799A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3229494A1 (en) * 2021-08-19 2023-02-23 Yun Kau Tam A pharmaceutical platform technology for drug discovery and consumer health product development

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790839B2 (en) 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
ATE292973T1 (de) 2001-01-16 2005-04-15 Can Fite Biopharma Ltd Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
AU2003274648A1 (en) * 2002-10-22 2004-05-13 Can-Fite Biopharma Ltd. The use of the a3 adenosine receptor as a marker for a diseased state
WO2004045627A1 (en) 2002-11-19 2004-06-03 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
AU2006321165B2 (en) 2005-11-30 2010-04-22 Can-Fite Biopharma Ltd. Use of A3 adenosine receptor agonist in osteoarthritis treatment
MX2007010896A (es) * 2007-09-06 2009-03-06 Univ Mexico Nacional Autonoma Uso de sales de adenosina para la preparacion de productos farmaceuticos para el tratamiento del cancer.
EP2227234B1 (en) 2007-10-15 2014-05-07 Can-Fite Biopharma Ltd. Method for inducing hepatocyte proliferation and uses thereof
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
IL200753A (en) 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
GB2494461A (en) * 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
US20130169785A1 (en) * 2011-12-30 2013-07-04 Agco Corporation Method of detecting and improving operator situational awareness on agricultural machines
EP2806878A1 (en) 2012-01-23 2014-12-03 Can-Fite Biopharma Ltd. Treatment of liver conditions
GB2515312A (en) * 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments

Also Published As

Publication number Publication date
JP2023510003A (ja) 2023-03-10
AU2021207766A1 (en) 2022-07-21
KR20220137661A (ko) 2022-10-12
IL272078A (en) 2021-07-29
EP4090324A1 (en) 2022-11-23
MX2022008850A (es) 2022-08-10
WO2021144799A1 (en) 2021-07-22
CN114980873A (zh) 2022-08-30
CA3164880A1 (en) 2021-07-22
US20230049415A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
Covelo et al. Lateral regulation of synaptic transmission by astrocytes
Zigmond et al. Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency
Gomes et al. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice
Chinta et al. Anti-inflammatory role of the isoflavone diadzein in lipopolysaccharide-stimulated microglia: implications for Parkinson’s disease
BR112022015377A2 (pt) Derivados de psilocina como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
Colla et al. Involvement of monoaminergic systems in the antidepressant-like effect of Eugenia brasiliensis Lam.(Myrtaceae) in the tail suspension test in mice
BR112021024686A2 (pt) Produto de bolsa de nicotina
CO2019013887A2 (es) Composiciones y tratamientos para el trastorno del sueño
Tardito et al. Synergistic mechanisms involved in the antidepressant effects of agomelatine
Paton et al. Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice
Bagheri et al. Anticonvulsant effect of Ferula assa-foetida oleo gum resin on chemical and amygdala-kindled rats
BR112015001158A2 (pt) formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia
US10596159B2 (en) Method and composition for treating cachexia and eating disorders
BR112022013991A2 (pt) Formulação para tratar uma doença ou distúrbio tratável por um agonista do receptor de adenosina a3 (a3ar), canabinoide, método de tratamento de uma doença ou distúrbio tratável por um agonista do receptor de adenosina a3 (a3ar) e método de tratamento de uma doença ou distúrbio em um sujeito
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
Bagheri et al. Antinociceptive activity of Astragalus gummifer gum (gum tragacanth) through the adrenergic system: A in vivo study in mice
Fogaça et al. Cannabinoids, neurogenesis and antidepressant drugs: is there a link?
BR112017007774A2 (pt) Um ou uma combinação dos fitocanabinoides canabidiol (cbd); canabidivarina (cbdv); e tetra- hidrocanabivarina (thcv), combinação dos fitocanabinoides, formulação farmacêutica, e, método para tratamento de um indivíduo que sofre de distrofia muscular de duchenne (dmd).
Khedgikar et al. Ethanolic extract of Dalbergia sissoo promotes rapid regeneration of cortical bone in drill-hole defect model of rat
BR112021025601A2 (pt) Derivado de indazole, método de preparação do mesmo, e aplicação farmacêutica do mesmo
BR112023000747A2 (pt) Composições para o tratamento de obesidade
Loucks et al. Molecular changes associated with teratogen‐induced cyclopia
PE20210974A1 (es) Composicion de cannabinoides y metodo para tratar el ptsd y/o la ansiedad
Salehi et al. Evaluation of the effective methods of seed dormancy breaking in medicinal plant of Bilhar (Dorema aucheri)
BR112018074496A2 (pt) composição biopesticida para uso na prevenção minimização de doenças de plantas